Sonoma Pharmaceuticals (SNOA) Gross Profit (2010 - 2026)

Sonoma Pharmaceuticals' Gross Profit history runs 17 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 42.74% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 35.68% increase from a year earlier, with the FY2026 full-year figure at $7.4 million, up 35.68% from the prior year.
• Gross Profit advanced to $2.2 million in Q1 2026 per SNOA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $2.2 million in Q1 2026 and bottomed at $96000.0 in Q1 2022.
• The 5-year median for Gross Profit is $1.4 million (2024), against an average of $1.3 million.
• Biggest YoY gain for Gross Profit was 800.0% in 2023; the steepest drop was 35.55% in 2023.
• Year by year, Gross Profit stood at $831000.0 in 2022, then jumped by 75.69% to $1.5 million in 2023, then retreated by 13.01% to $1.3 million in 2024, then increased by 29.92% to $1.6 million in 2025, then soared by 32.18% to $2.2 million in 2026.
• Per Business Quant, the three latest SNOA Gross Profit figures stand at $2.2 million (Q1 2026), $1.6 million (Q4 2025), and $2.1 million (Q3 2025).